JPRN-UMIN000020647
Completed
Phase 2
A randomized, double-blind, placebo-controlled study to evaluate efficacy and safety of OSD-001 in primary palmar hyperhidrosis (Phase II study) - A clinical trial to evaluate the efficacy and safety of OSD-001 (a gel formulation containing sirolimus) in patients with primary palmar hyperhidrosis
ConditionsPrimary palmar hyperhidrosis
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Primary palmar hyperhidrosis
- Sponsor
- Osaka University Hospital
- Enrollment
- 45
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)Subjects who received a surgical treatment including the sympathetic nerve interception within 12 months prior to the study\-entry . 2\)Subjects who received a treatment with Sirolimus, Everolimus or Temsirolimus within 6 months prior to the study\-entry. 3\) Subjects who received a treatment with botulinum toxin within 12 months prior to the study\-entry . 4\) Subjects who received a treatment with aluminum chloride solution or iontophoresis within a month prior to the study\-entry . 5\) Subjects who received a treatment with anticholinergic drug or antihistamine drug within two weeks prior to the study\-entry .
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Phase 3
A randomized, double-blind, placebo-controlled study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and long term efficacy up to 2 years in patients with active rheumatoid arthritis who have an inadequate response to anti-TNF-alpha agentsRheumatoid ArthritisJPRN-jRCT2080221561ovartis Pharma K.K.
Active, not recruiting
Not Applicable
A randomized, double-blind, placebo-controlled study to assess the effect of Tamsulosin OCAS 0.4 mg tablets, once daily on nocturia, compared to placebo, in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia - RESTORETS (lower urinary tract symptoms) associated with BPH (benign prostatic hyperplasia)EUCTR2005-001627-11-PTYamanouchi Europe B.V. (to be renamed Astellas Pharma Europe B.V., as of August 2005)1,051
Active, not recruiting
Not Applicable
A randomized, double-blind, placebo-controlled study to assess the effect of Tamsulosin OCAS 0.4 mg tablets, once daily on nocturia, compared to placebo, in patients with lower urinary tract symptoms associated with benign prostatic hyperplasiaEUCTR2005-001627-11-ITYAMANOUCHI PHARMA882
Active, not recruiting
Not Applicable
A randomized, double-blind, placebo-controlled study to assess the effect of Tamsulosin OCAS 0.4 mg tablets, once daily on nocturia, compared to placebo, in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia - RESTOREEUCTR2005-001627-11-FIYamanouchi Europe B.V. (to be renamed Astellas Pharma Europe B.V., as of August 2005)1,051
Active, not recruiting
Phase 1
Evaluation of Efficacy and Safety of Sarilumab in Patients with GCAGiant Cell ArteritisMedDRA version: 20.0Level: LLTClassification code 10018250Term: Giant cell arteritisSystem Organ Class: 100000004866Therapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2017-002988-18-BESanofi-Aventis Recherche & Développement508